[177Lu]LU-PSMA-I&T is a type of targeted therapy used in this clinical trial for patients with a specific kind of prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatments. This therapy works by delivering a radioactive substance directly to the cancer cells, which helps to destroy them while minimizing damage to the surrounding healthy tissue. The goal of using this treatment is to slow down the progression of the cancer and improve the patient’s quality of life.

Hormone Therapy is another treatment option being compared in this trial. It is used to treat prostate cancer by reducing the levels of male hormones, like testosterone, which can help slow the growth of cancer cells. Hormone therapy can be administered in various forms, such as pills or injections, and is often used when the cancer has become resistant to initial treatments. The aim is to control the cancer’s progression and alleviate symptoms associated with the disease.

Metastatic Castration-Resistant Prostate Cancer (mCRPC) – This is a form of prostate cancer that continues to progress despite treatments that lower testosterone levels. It is characterized by the spread of cancer cells beyond the prostate gland to other parts of the body, such as bones and lymph nodes. The disease progresses as cancer cells grow and multiply, often leading to increased pain and other symptoms. Over time, the cancer may become resistant to hormone therapy, which is initially used to control its growth. As the disease advances, patients may experience a range of symptoms related to the spread of cancer, including bone pain and urinary issues. The progression of mCRPC is typically monitored through imaging studies and blood tests to assess the extent of cancer spread and activity.